OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA

NCT06820502 | Active Not Recruiting DMC

• 1 other identifier: ERB179/8/23-12-2024/S1ERB
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The rationale of my study is that studies have shown that between 50% and 70% of patients treated with trans-urethral bladder tumor resection (TURBT) alone for NMIBC have recurrence with stage and grade progression in 10% to 15% and because of this theoretical danger of tumor cell implantation, many urologists avoid simultaneous trans-urethral prostate resection (TURP) and TURBT due to fear of implantation of tumor cells in the denuded areas of the resected prostate and prefer to perform a separate procedure for each pathological condition. However, others observed no deleterious effects of simultaneous TURBT and TURP. This unsettled controversy that has spanned almost 4 decades. This study will delineate guidelines for outcome of these procedures in terms of better prognosis for patients. OBJECTIVE: The objective of the study is to compare the outcome of simultaneous trans-urethral bladder tumor and prostate resection versus trans-urethral bladder tumor resection alone in bladder tumor with prostate hyperplasia in terms of in terms of recurrence of bladder tumor SUBJECTS AND METHODS Study Design: Randomized controlled trial Settings: Department of Urology, Jinnah Hospital and Allama Iqbal Medical College, Lahore. Study Population: Patients who will undergo TURP and TURBT at Jinnah Hospital, Lahore will be study population. Duration of study: 3 months after approval of synopsis. Sampling Technique: Non-Probability / consecutive Sampling Sample Size: Sample size calculated with 80 % power of study and 5 % level of significance Assumed recurrence rate of simultaneous trans-urethral bladder tumor resection with prostate resection (Group A) = 53.6% Assumed recurrence rate of trans-urethral bladder tumor resection alone (Group B) = 86.9% Required sample size of total of 60 patients (30 patients in each group) SAMPLE SELECTION: Inclusion Criteria

• Males aged 40 - 65 year
• First diagnosis of bladder neoplasm less than 4 cm, confined in urinary bladder
• Prostate volume ≥ 40 and ≤ 80 ml with normal PSA level and obstructive voiding symptoms Exclusion Criteria
• Patients with previous prostatic, urethral surgery and urinary bladder surgery like diverticulectomy, ureteric reimplant in urinary bladder
• Patients with coagulopathy
• Previous history of heart diseases
• Diagnosis of prostate cancer
• Urethral stenosis, previous pelvic irradiation, and neurogenic bladder.
• Recurrent Bladder Tumor DATA COLLECTION PROCEDURE: The study involves 60 male patients diagnosed with bladder carcinoma, meeting inclusion criteria. Informed consent, emphasizing data confidentiality, will be obtained. Patients will be thoroughly examined at Jinnah Hospital Lahore. Preoperative assessment includes medical history, physical examination, digital rectal examination, PSA assay, and IPSS. Patients will be randomly assigned one of two treatments through a computer aided randomization. Patients will be followed with preoperative protocols, and undergo procedures under spinal anesthesia. In group A trans-urethral resection with a resectoscope is employed for both TURBT and TURP. In Group B TURBT, a wire loop electrode through the cystoscope removes bladder tumors in small pieces. TURP involves the resectoscope removing prostate tissue in small fragments, controlled by electrocautery. Post-surgery, complications were dealt with. Tissue fragments are sent to the lab for histopathological analysis. Follow-ups adhere to EAU guidelines, recording recurrence and UTI presence. Histopathology reports follow the 2004 WHO classification. The primary outcome recurrence rate will be noted in 3 months. All the information will be collected in a structured questionnaire.

Conditions

Bladder Cancer Recurrence; BPH (Benign Prostatic Hyperplasia); Bladder Cancer

Outcome Measures

Primary Outcomes (1)

• Bladder Tumor Recurrence

  RECURRENCE OF TUMOUR: Recurrence refers to the return of bladder cancer after initial treatment. It can occur in the remaining bladder tissue (if partial cystectomy was performed), in the area where the bladder was removed or in nearby lymph nodes. Recurrence will be measured through regular follow-up cystoscopies and imaging studies (such as ct scans) as recommended by EAU guidelines. Any suspicious findings will be biopsied and confirmed through histopathology. It will be assessed after three months of surgery.

  after 3 months of surgery

Study Arms (2)

Patients undergoing TURBT and TURP simultaneously

EXPERIMENTAL

Patients undergoing TURBT and TURP simultaneously for Bladder tumour and Benign Prostatic Hyperplexia

Procedure: Transurethral Resection of Prostate (TURP); Procedure: Transurethral Resection Of Bladder Tumor

Patients undergoing TURBT

EXPERIMENTAL

Patients undergoing TURBT only for Bladder Tumour and BPH

Procedure: Transurethral Resection Of Bladder Tumor

Interventions

Transurethral Resection of Prostate (TURP) PROCEDURE

TURP: Transurethral resection of the prostate remains the criterion standard therapy for obstructive prostatic hypertrophy and is both the surgical treatment of choice and the standard of care when medication fails. It improves obstructive voiding symptoms and urinary flow rate with success rates ranging from 85 to 90% .

Patients undergoing TURBT and TURP simultaneously

Transurethral Resection Of Bladder Tumor PROCEDURE

TURBT: Trans-urethral resection of bladder tumor (TURBT), performed endoscopically, is the firstline procedure for diagnosis, staging, and treatment of visible bladder tumors,

Patients undergoing TURBT; Patients undergoing TURBT and TURP simultaneously

Eligibility Criteria

• Age: 40 Years - 65 Years
• Gender Eligibility Details: Prostate is the organ in the male genital system specifically, its absent in females
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males aged 40 - 65 year
• First diagnosis of bladder neoplasm less than 4 cm, confined in urinary bladder
• Prostate volume \> 40 and \< 80 ml with normal PSA level and obstructive voiding symptoms

You may not qualify if:

• Patients with previous prostatic, urethral surgery and urinary bladder surgery Iike diverticulectomy, ureteric reimplant in urinary bladder Patients with coagulopathy Previous history of heart diseases Diagnosis of prostate cancer Urethral stenosis, previous pelvic irradiation, and neurogenic bladder. Recurrent Bladder Tumor

Sponsors & Collaborators

• Allama Iqbal Medical College: lead

Study Sites (1)

Department of Urology and Renal Transplant, Jinnah Hospital Lahore/ Allama Iqbal Medical College

Lahore, Punjab Province, 54550, Pakistan

Location

MeSH Terms

Conditions

Prostatic Hyperplasia; Urinary Bladder Neoplasms

Interventions

Transurethral Resection of Prostate; Transurethral Resection of Bladder

Condition Hierarchy (Ancestors)

Prostatic Diseases; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Male Urogenital Diseases; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urinary Bladder Diseases; Urologic Diseases

Intervention Hierarchy (Ancestors)

Prostatectomy; Urologic Surgical Procedures, Male; Urologic Surgical Procedures; Urogenital Surgical Procedures; Surgical Procedures, Operative

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Post Graduate Resident

Study Record Dates

• First Submitted: February 6, 2025
• First Posted: February 11, 2025
• Study Start: August 15, 2024
• Primary Completion: December 31, 2024
• Study Completion: January 31, 2025
• Last Updated: February 11, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will share

Locations

PA (1)